SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to a lawsuit from Singapore's GIC alleging inflated revenue figures, sparking debate about its impact. The community is divided, with some viewing it as a buying opportunity amidst recycled headlines and others expressing concern. Discussions also include delivery numbers, battery swap technology, and the broader context of Chinese EV competition.

Veritone, Inc. engages in the provision of artificial intelligence (AI) computing solutions to media and entertainment, government, and legal and compliance industries. It operates through the following segments: Advertising, aiWARE SaaS Solutions, and aiWARE Content Licensing and Media Services. The Advertising segment places advertisements for clients, primarily with radio broadcasters, podcasters and digital media producers. The aiWARE SaaS Solutions segment offers solutions through a combination of its direct sales force and indirect channel partners, such as value-added resellers (VARs), distributors, system integrators, managed services providers, and referral partners. The aiWARE Content Licensing and Media Services segment sells and markets activities relating to its digital content licensing services business through its direct sales force. The company was founded by Chad Edward Steelberg and Ryan S. Steelberg on June 13, 2014 and is headquartered in Denver, CO.

Veritone Inc

Veritone (VERI) is trending due to a registered direct offering of $75 million, leading to community discussion about dilution and management's timing. While some investors express concerns about the offering's impact on share value, others view it as a necessary step for growth and debt repayment, emphasizing the company's long-term potential in the AI sector. Community members are actively debating whether this dip presents a buying opportunity or signals further downside.

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

MVST is trending as investors discuss its valuation relative to peers and potential catalysts like earnings and expansion plans. Community members are pointing to potential short squeezes and institutional buying, while also debating the company's ties to China. Overall, the discussion revolves around whether the stock is undervalued and poised for further gains.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxis Precision Medicines is trending due to positive topline results from Phase 3 trials of ulixacaltamide HCl for essential tremor, sparking significant pre-market gains and heavy trading volume. The community is focused on the high institutional ownership potentially leading to a short squeeze, with some speculating on price targets. This movement occurs within the context of the essential tremor treatment space, where there is a large unmet need for effective therapies.

Aurora Innovation, Inc. engages in the design and development of automobile hardware, software, and provision of data services. It offers the Aurora Driver which allows a vehicle to drive itself. The company was founded by Christopher Urmson, Sterling Anderson and James Andrew Bagnell in 2017 and is headquartered in Pittsburgh, PA.

Aurora Innovation Inc - Ordinary Shares - Class A

Aurora Innovation is trending as the community discusses the potential impact of new partnerships and upcoming earnings. Bullish sentiment is fueled by institutional buying, progress in autonomous trucking technology, and analysts setting high price targets. Discussions also revolve around the company's path to commercialization and its competitive positioning within the autonomous vehicle sector.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending after reporting strong Q3 earnings, driven by surging AI chip demand, and raising its 2025 revenue growth outlook. Community members are discussing the company's impressive profit increase and potential for further gains, while also noting geopolitical risks. Some analysts are raising price targets, citing TSMC's key role in the AI boom and strong guidance.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending as analysts update their ratings, citing a clear path to growth and potential investor sentiment improvement, especially with the company's AI integrations. Community discussions revolve around potential revival of the AI software/enterprise trade and possible short-term trading opportunities. The stock also garnered attention following Salesforce and Google's deepened partnership with Gemini integration, further emphasizing the company's focus on AI.

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

Bitfarms is trending as investors discuss its recent financing deal involving capped calls, which some believe will fuel expansion while others are skeptical about its use. Community members are debating the potential for dilution and its impact on the stock's future growth, with some drawing comparisons to other Bitcoin miners that have undertaken similar strategies. Bullish sentiment remains strong overall, fueled by the company's shift towards high-performance computing (HPC) and artificial intelligence (AI) infrastructure.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending due to renewed interest in AI-driven drug discovery and speculation of an impending short squeeze, with the community noting NVIDIA's backing and a high short float. Discussions revolve around the potential for a breakout, drawing parallels to other stocks that have experienced significant rallies. Bullish investors are eyeing upcoming presentations and potential expansion opportunities.

SharpLink Gaming, Inc. is an online performance-based marketing company, which engages in the provision of online platform facilitating sports betting. It connects sports fans, leagues, and sports websites to relevant and timely sports betting content. The company was founded by Robert Phythian in 2019 and is headquartered in Minneapolis, MN.

SharpLink Gaming Inc.

SharpLink Gaming Ltd

SBET is trending due to positive analyst ratings and a direct offering priced at a premium, sparking community discussion about its potential upside, particularly in relation to its ETH holdings. Some traders are optimistic about a potential breakout, while others express concerns about dilution and compare its performance to other digital asset treasury stocks like BMNR. The stock's correlation with ETH's price movements remains a key point of discussion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Solid Biosciences drew heightened retail chatter on Tuesday following&nbsp;approvals for human trials by U.S. and Canadian regulators to test its gene therapy,&nbsp; SGT-501, for a life-threatening heart rhythm condition&nbsp;called catecholaminergic polymorphic ventricular tachycardia (CPVT).This inherited disorder commonly affects children and young adults who experience dangerous arrhythmias when stressed or exercising with no existing FDA-approved treatments available in the U.S.Shares of the Charlestown, Massachusetts-based company, which ended Tuesday more than 6% higher, gained over 4% in after-hours trading following the announcement.Solid Biosciences&nbsp;plans to launch a Phase 1b trial later this year to determine the safety and effectiveness of the therapy.&nbsp;SGT-501 holds Orphan Drug and Rare Pediatric Disease designations in the U.S. that offer development and commercialization incentives, including extended exclusivity, and accelerated reviews when the drug candidate enters an approval application stage.The treatment employs a viral tool to introduce a functional CASQ2 gene into cardiac muscle cells.&nbsp;The CASQ2 gene&nbsp;encodes a protein essential for heart cells to maintain&nbsp;regular calcium release and uptake during each heartbeat.&nbsp;The genetic changes found in CPVT patients result in&nbsp;a disruption of&nbsp;calcium flow, which triggers abnormal heart rhythms.The company is also advancing SGT-003, a gene therapy candidate for Duchenne muscular dystrophy (DMD).&nbsp;Last week, Citi initiated coverage on Solid with a&nbsp;‘Buy’ rating and a $14 price target, citing favorable risk-reward dynamics and a cleaner safety profile for SGT-003 compared to Sarepta’s Elevidys, which has been&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-pauses-dmd-gene-therapy-trial-after-second-death-retail-traders-brush-off-risk/chlnJFARRbY">under scrutiny</a> following reports of liver-related fatalities.H.C. Wainwright also maintained a ‘Buy’ rating on Solid, calling SGT-003 the most promising DMD gene therapy currently in development or on the market.On Stocktwits, retail sentiment for Solid was ‘extremely bullish’ amid ‘extremely high’ message volume.One user reflected on a missed opportunity, noting they “hesitated to add more” at $2.40 and now “regret it,” saying they should have purchased at least 800 shares.&nbsp;<stembedurl>https://stocktwits.com/Rolex53/message/620276017</stembedurl>Another user questioned whether the post-news spike to $5.80 was the peak, acknowledging the announcement as “critical confirmation of our product pipeline,” but also cautioning that it’s not the same as fast-tracking or trial success.<stembedurl>https://stocktwits.com/The_Red_Fox/message/620258395</stembedurl><a href="https://stocktwits.com/symbol/SLDB">SLDB’s stock</a> has risen 34.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Solid Biosciences (SLDB) got approvals for human trials by U.S. and Canadian regulators to test its gene therapy,  SGT-501/ Photo credit: Getty Images

Solid Biosciences Stock Pops On US, Canada Nod For Gene Therapy Trials: Retail Buzz Spikes

The company plans to begin a Phase 1b trial of SGT-501 later this year, targeting CPVT, a rare and potentially fatal arrhythmia in children and young adults with no current FDA-approved therapies.

Equity

Stock market today: S&P 500 in Q1 loss despite jump; 'liberation day' tariffs loom

Investing.com-- The S&P 500 closed higher Monday, as a dip to six-month lows drew support, but the index ended the first quarter lower just days ahead of President Donald Trump’s April 2 "liberation day" deadline to impose more reciprocal tariffs. 

Candel Therapeutics Inc. (13% jump in followers)Candel Therapeutics Inc. shares gained momentum as Wall Street analysts&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">highlighted</a> the potential of its lead cancer drug candidate, CAN-2409. Canaccord expects continued clinical success in prostate, pancreatic, and non-small cell lung cancer, noting a significant increase in median overall survival in testing so far. Citi’s modeling suggests CAN-2409 could extend survival in localized prostate cancer by as much as eight to nine years over radiotherapy alone.&nbsp;The stock is up over 35% year-to-date.Acelyrin Inc. (12% jump in followers)Acelyrin confirmed that Concentra Biosciences, controlled by Tang Capital Partners, submitted an unsolicited offer to acquire all outstanding shares of Acelyrin for $3.00 per share in cash, plus a contingent value right tied to future licensing or asset sales.Earlier in the month, Acelyrin announced a merger agreement with Alumis in an all-stock transaction expected to close in the second quarter of 2025, pending shareholder approval.&nbsp;Acelyrin stock is down over 18% year-to-date.Solid Biosciences Inc. (11% jump in followers)Solid Biosciences shares surged after early-stage data from its gene therapy candidate SGT-003 for Duchenne muscular dystrophy&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sldb-stock-soars-on-dmd-trial-data/ch5rNeJRvt">showed</a> promising results.&nbsp;Following the data release, Chardan raised its price target on the stock and increased the therapy’s probability of success to 48%, citing strong early efficacy signals and manageable safety risks.Solid Biosciences stock is up 43% year-to-date.Estrella Immunopharma Inc. (11% jump in followers)Estrella Immunopharma received a bullish initiation from D. Boral Capital, which started coverage with a ‘Buy’ rating and a $16 price target. The firm sees Estrella as a potential major player in immuno-oncology, with its EB103 therapy using ARTEMIS T-cell engineering technology to target solid tumors.&nbsp;The company also completed the first dose cohort in its Phase I/II trial, receiving approval from the Data and Safety Monitoring Board to proceed to the second dose level.&nbsp;Estrella stock is up over 22% year-to-date.Aditxt Inc. (10% jump in followers)Aditxt announced that its subsidiary, Pearsanta, has engaged Dominari Securities as the lead underwriter for its planned initial public offering. The IPO aims to support Pearsanta’s U.S. and international commercial launch of its Mitomic Technology platform for early cancer detection.&nbsp;Pearsanta is developing a non-invasive blood test to detect cancer at earlier stages by leveraging mitochondrial DNA deletions as biomarkers. IPO proceeds will fund the U.S. launch of its Laboratory Developed Tests (LDTs) and drive global commercialization through distribution partnerships and regulatory approvals.&nbsp;Aditxt stock is down over 53% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended gains in after-hours trading. On Stocktwits, the ticker's retail followers jumped by 11%.Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results.Interim 90-day biopsy data from the Phase 1/2 trial showed:<ul style="list-style-type:square;"><li>110% average microdystrophin expression (via western blot) in the first three participants</li><li>Improvements in multiple biomarkers, indicating better muscle health and resilience</li><li>SGT-003 was well-tolerated, with no serious adverse events or signs of major complications like thrombotic microangiopathy</li></ul>&nbsp;Adverse events included nausea, vomiting, fever, and transient platelet declines—which the company said were typical for adeno-associated virus gene therapy—but none required additional immunomodulatory treatments.Following the data, according to The Fly, Chardan raised its price target on Solid Biosciences to $16 from $15, implying more than a 200% upside from Tuesday’s close.&nbsp;The research firm also increased the therapy's probability of success to 48%, citing strong early efficacy signals and manageable safety.Retail sentiment on Stocktwits turned 'extremely bullish,' with message volume skyrocketing over 5,500% to the highest level in three months.One user commented that the "real appreciation" for the stock will start "once the day traders leave."<stembedurl>https://stocktwits.com/pharmd2828/message/604696890</stembedurl>Another suggested the stock could "double in no time" based on "pretty compelling data."<stembedurl>https://stocktwits.com/iSmith/message/604695964</stembedurl>Early results from a Stocktwits poll showed 49% of respondents believe SGT-003 could be a blockbuster, while 20% think it's "just hype."<figure class="image"><img style="aspect-ratio:1314/1062;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SLDB_poll_and_sentiment_meter_on_Feb_18_7c2cbe8810.png" alt="SLDB poll and sentiment meter on Feb 18.png" width="1314" height="1062"><figcaption>SLDB poll and sentiment meter on Feb 18 | source: Stocktwits</figcaption></figure>Separately, Solid Biosciences announced a $200 million underwritten offering, pricing 35.7 million common shares at $4.03 per share and 13.9 million pre-funded warrants at $4.029 apiece. The offering is set to close on Wednesday.According to Koyfin, short interest on SLDB has climbed from 4.4% at the start of the year to 6.6%.<a href="https://stocktwits.com/symbol/SSRM">Solid Biosciences stock</a> is now up over 31% this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?

Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results.

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases...

Solid Biosciences' SGT-003 receives rare pediatric disease designation

Duchenne is a genetic disorder, primarily affecting boys and is known to be fatal. This disease is claimed to affect roughly one in every 3,500 to 5,000 live
The post Solid Biosciences' SGT-003...

Solid Biosciences (SLDB, $12.44) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This indicator may be signaling that SLDB's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Solid Biosciences (SLDB, $12.44) Moving Average Convergence Divergence (MACD) Histogram turned negative on April 1, 2024

This is a Bearish indicator signaling SLDB's price could decline from here. Traders may explore shorting the stock or put options...

Solid Biosciences receives Rae Pediatric Disease designation for SGT-003

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 CHARLESTOWN, Mass...

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Solid Biosciences Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

SLDB
Solid Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SLDB News

SLDBSolid Biosciences Inc